- Home
- GSL vs OPT Comparison
GSL vs OPT Comparison
Compare GSL & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- OPT
- Stock Information
- Founded
- GSL 2007
- OPT 1984
- Country
- GSL Greece
- OPT Australia
- Employees
- GSL N/A
- OPT N/A
- Industry
- GSL Marine Transportation
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GSL Consumer Discretionary
- OPT Health Care
- Exchange
- GSL Nasdaq
- OPT Nasdaq
- Market Cap
- GSL 753.1M
- OPT 767.9M
- IPO Year
- GSL 2006
- OPT 2020
- Fundamental
- Price
- GSL $21.23
- OPT $3.34
- Analyst Decision
- GSL Strong Buy
- OPT Strong Buy
- Analyst Count
- GSL 1
- OPT 1
- Target Price
- GSL $29.00
- OPT $12.00
- AVG Volume (30 Days)
- GSL 401.9K
- OPT 12.3K
- Earning Date
- GSL 11-11-2024
- OPT 08-30-2024
- Dividend Yield
- GSL 7.76%
- OPT N/A
- EPS Growth
- GSL 7.30
- OPT N/A
- EPS
- GSL 8.96
- OPT N/A
- Revenue
- GSL $701,476,000.00
- OPT $261,859.00
- Revenue This Year
- GSL $6.45
- OPT N/A
- Revenue Next Year
- GSL N/A
- OPT $46,864.64
- P/E Ratio
- GSL $2.37
- OPT N/A
- Revenue Growth
- GSL 8.60
- OPT N/A
- 52 Week Low
- GSL $18.75
- OPT $1.79
- 52 Week High
- GSL $30.32
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- GSL 34.07
- OPT 43.16
- Support Level
- GSL $21.10
- OPT $3.15
- Resistance Level
- GSL $21.89
- OPT $3.39
- Average True Range (ATR)
- GSL 0.60
- OPT 0.18
- MACD
- GSL 0.00
- OPT -0.00
- Stochastic Oscillator
- GSL 16.18
- OPT 27.49
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.